Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: PAL who wrote (3295)	12/12/1997 1:46:00 AM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Another view on this weeks presentation by Agouron from BancAmerica Robertson Stephens (12/10/97): "2. AG3340Has excellent oral absorption, Phase II/Pivotal Trial to Begin in Q1:98. In what would be a unique twice-a-day (or even once -a-day) pill, AG3340 has been tested in several preclinical cancer models and five doses (5, 10, 25, 50 and 100 milligrams per day) in patients with various solid tumors. As a slective MMP inhibitor, AG3340 appears more potent as a tumorstatic (i.e. stops tumors from growing) agent than British Biotech's (BBIoy $17-1/2) Marimastat. Exposures equivalent to those effective in preclinical models are easily achieved in humans in very low concentrations/doses. In addition, exposure levels being explored cover the spectrum of cancers. In addition to the doses mentioned above, the company is adding cohorts of drug at the 1 and 2 milligram levels, further supporting the drug's potency. Phase II randomized, controlled and blinded studies in combination with other chemotherapy agents will begin in Q1:98, in small cell lung cancer and hormone refractory prostrate cancer, that could turn into pivotal trials. Other disease potential include giloma, breast and colon cancer."